Oncostatin M as a Complementary Non-Invasive Marker of Endoscopic and Histological Disease Activity in Ulcerative Colitis
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188110 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Alina-Ecaterina Jucan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Oncostatin M, Biomarkers. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: INNODOC-MED.
Abstract (Originalsprache)
Plasma Oncostatin M (OSM) has been proposed as a biomarker of disease activity in ulcerative colitis (UC). We evaluated OSM’s relationship with clinical, endoscopic, and histological activity across two follow-up visits, compared with fecal calprotectin (FC). One hundred UC patients were assessed at Visit 1 (baseline) and Visit 2 (12 months) for clinical (partial Mayo score), endoscopic (Mayo Endoscopic Score), and histological (Nancy Histological Index) activity, alongside plasma OSM, FC, CRP, and fibrinogen; 30 healthy controls were included for comparison. Given the marked right-skewness of OSM and FC, associations were assessed using both Pearson and Spearman correlations, and logistic regression effect sizes are reported as odds ratios per doubling of biomarker concentration (log2 scale). OSM correlated significantly with all activity measures at both visits, most strongly with histological activity (r = 0.521–0.602), but weakly or not with CRP/fibrinogen. OSM was significantly elevated versus controls at both visits (p < 0.001) and declined significantly with treatment response (Δ = −89.06 vs. +0.50 in controls, p = 0.006). FC was the dominant predictor of clinical (AUC = 0.788) and endoscopic (AUC = 0.926) remission at Visit 2, with OSM contributing little independent value; however, for histological remission, both baseline OSM and ΔOSM were independent, complementary correlates (OR = 8.43 and 9.64 per doubling, respectively; p < 0.001 for both), yielding the strongest model overall (AUC = 0.949). OSM’s discriminative accuracy improved markedly from Visit 1 to Visit 2 for endoscopic (AUC 0.695 → 0.897) and histological (AUC 0.738 → 0.927) activity. Across two follow-up assessments, OSM consistently reflected UC activity, with its strongest and most independent signal for histological inflammation, both as a concurrent correlate and—more modestly—as a genuine prospective marker independent of baseline treatment exposure. OSM’s incremental value over FC was most apparent for histological status and for stringent (MES 0) endoscopic remission, but not for conventional clinical or endoscopic remission thresholds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
- Department of Gastroenterology, Institute of Gastroenterology and Hepatology, "St. Spiridon" County Clinical Emergency Hospital, 700111 Iasi, Romania.
- Department of Radiology, "St. Spiridon" County Clinical Emergency Hospital, 700115 Iasi, Romania.
- Department of Immunology, "St. Spiridon" County Clinical Emergency Hospital, 700111 Iasi, Romania.
- Department of Animal Resources and Technologies, Faculty of Food and Animal Sciences, "Ion Ionescu de la Brad" University of Life Sciences, 700489 Iasi, Romania.
- Department of Internal Medicine Clinic, "St. Spiridon" County Clinical Emergency Hospital, 700111 Iasi, Romania.
ORCID-Profile: Georgiana-Elena Sarbu, Vasile-Claudiu Mihai, Ioana-Irina Rezuș, Mariana Pavel-Tanasa, Daniela Constantinescu, Vasile Maciuc, Daniela Maria Tanase, Vasile Drug
Förderung
- INNODOC-MED
Zitieren
APA
Jucan, A. E., Atodiresei, C., Sarbu, G. E., Mihai, V. C., Rezuș, I. I., Juncu, S., Pavel-Tanasa, M., Constantinescu, D., Maciuc, V., Dranga, M., Nedelciuc, O., Barboi, O., Ciortescu, I., Tanase, D. M., Hancianu, M., Drug, V., Cijevschi-Prelipcean, C., & Mihai, C. (2026). Oncostatin M as a Complementary Non-Invasive Marker of Endoscopic and Histological Disease Activity in Ulcerative Colitis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188110
Vancouver
Jucan AE, Atodiresei C, Sarbu GE, Mihai VC, Rezuș II, Juncu S, et al. Oncostatin M as a Complementary Non-Invasive Marker of Endoscopic and Histological Disease Activity in Ulcerative Colitis. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188110
BibTeX
@article{Jucan2026,
author = {Jucan, Alina-Ecaterina and Atodiresei, Carmen and Sarbu, Georgiana-Elena and Mihai, Vasile-Claudiu and Rezuș, Ioana-Irina and Juncu, Simona and Pavel-Tanasa, Mariana and Constantinescu, Daniela and Maciuc, Vasile and Dranga, Mihaela and Nedelciuc, Otilia and Barboi, Oana and Ciortescu, Irina and Tanase, Daniela Maria and Hancianu, Monica and Drug, Vasile and Cijevschi-Prelipcean, Cristina and Mihai, Cătălina},
title = {Oncostatin M as a Complementary Non-Invasive Marker of Endoscopic and Histological Disease Activity in Ulcerative Colitis},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188110}
}
EUVIMED